Drug ‘breakthrough’ gives longest-ever survival in non-resectable liver cancer patients
The IMbrave150 trial found median overall survival was 19.2 months in patients treated with atezo…
Browsing: bevacizumab
Response to adjuvant bevacizumab among patients with resected melanoma may vary by age
Younger patients with resected melanoma had some benefit from adjuvant treatment with the anti-VEGF therapeutic…
New treatment extends lives of people with most common type of liver cancer
For the first time in over a decade, scientists have identified a first-line treatment that…
FDA approves olaparib plus bevacizumab as maintenance treatment for ovarian, fallopian tube, or primary peritoneal cancers
The Food and Drug Administration (FDA) expanded the indication of olaparib to include its combination…
Addition of cancer vaccine to bevacizumab may improve outcomes in patients with EGFRvIII-positive recurrent glioblastoma
“There is increasing evidence that vaccines can be efficacious for the treatment of cancer,” said…
ASCO GI: New drug combinations maintain quality of life for patients with colorectal and liver cancers
Patient-reported outcomes from two large studies show that quality of life is maintained longer with…
ESMO 2019: More ovarian cancer patients benefit from maintenance combined targeted therapy
New data presented at the ESMO Congress 2019 in Barcelona, Spain, show the benefit of a more…
Right-sided colorectal tumors: An internal radiation advantage
For patients with colorectal cancer that has metastasised to the liver, having a primary tumour…
New biomarker allows better prediction of survival for patients with colorectal metastases
Liver metastases are formed from cancer cells that have originated in other organs and migrated…
Peptide-based vaccination against VEGF results in efficient antitumour activity
A research team including professor Peter Timmerman of the University of Amsterdam’s Van ‘t Hoff…